4//SEC Filing
Maimon Yossi 4
Accession 0001209191-10-049835
CIK 0001006281other
Filed
Oct 7, 8:00 PM ET
Accepted
Oct 8, 4:10 PM ET
Size
11.8 KB
Accession
0001209191-10-049835
Insider Transaction Report
Form 4
Maimon Yossi
VP, Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2010-10-07$0.97/sh+77,769$75,591→ 0 total(indirect: By Trust) - Sale
Common Stock
2010-10-07$9.67/sh−70,000$676,900→ 0 total(indirect: By Trust) - Tax Payment
Common Stock
2010-10-07$9.73/sh−7,769$75,592→ 0 total(indirect: By Trust) - Exercise/Conversion
Stock Options (Right to Buy)
2010-10-07−77,769→ 75,964 totalExercise: $0.97Exp: 2016-09-19→ Common Stock (77,769 underlying)
Footnotes (5)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The reporting person acquired 70,000 shares of common stock upon the exercise of 77,769 outstanding options on a cash-less exercise basis, all of which shares were sold by the reporting person. The Company retained 7,769 shares of common stock in connection with the cashless exercise.
- [F3]qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee upon the exercise of stock options must be registered in the name of a trustee.
- [F4]All options are fully vested.
- [F5]Does not include options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019, does not include 130,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020 and does not include options to purchase 175,000 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018.
Documents
Issuer
Protalix BioTherapeutics, Inc.
CIK 0001006281
Entity typeother
Related Parties
1- filerCIK 0001385115
Filing Metadata
- Form type
- 4
- Filed
- Oct 7, 8:00 PM ET
- Accepted
- Oct 8, 4:10 PM ET
- Size
- 11.8 KB